Institutional Ownership
Lantern Pharma Inc
CUSIP 51654W101COMLTRNQ1 2026
13D / 13G Filings
14
Schedule 13D/13G on record
Beneficial Filers
9
Distinct reporting persons
Largest Stake
16.8%
Max % of class reported
Institutional Holders
29
13F filers (latest quarter)
Beneficial Owners — Schedule 13D / 13G
14 filings · latest Feb 23, 2026
| # | Filed | Reporting Person | Form | % of Class | Shares | Filing |
|---|---|---|---|---|---|---|
| 1 | Feb 23, 2026 | Bios Fund I, LP | 13D/A | 8.6% | — | SEC |
| 2 | Jun 13, 2025 | Bios Fund I, LP | 13D/A | 10.0% | — | SEC |
| 3 | Mar 1, 2024 | Bios Equity Partners, LP | 13D/A | 3.5% | 371.9K | SEC |
| 4 | Feb 14, 2024 | Prophase Labs, Inc. | 13G/A | 8.0% | 631.2K | SEC |
| 5 | Dec 1, 2023 | Bios Equity Partners, LP | 13D/A | 3.5% | 371.9K | SEC |
| 6 | Nov 21, 2022 | Prophase Labs, Inc. | 13G | 8.4% | 910.0K | SEC |
| 7 | Mar 22, 2022 | Bios Equity Partners, LP | 13D/A | 5.2% | 564.0K | SEC |
| 8 | Jan 11, 2022 | Empery Asset Management, LP | 13G/A | — | — | SEC |
| 9 | Feb 16, 2021 | Green Park & Golf Ventures, LLC | 13G | 1.4% | 147.5K | SEC |
| 10 | Feb 16, 2021 | Asaithambi Arunkumar | 13G | 4.5% | 470.5K | SEC |
4 more beneficial-ownership filings on Premium
See the full Schedule 13D/13G history for Lantern Pharma Inc.
Unlock full historyTop Institutional Holders (13F)
Largest reported positions · latest quarter
| # | Fund | Shares | Value |
|---|---|---|---|
| 1 | Bios Capital Management, LP | 864.4K | $1.18M |
| 2 | Cm Management, LLC | 250.0K | $342.5K |
| 3 | Renaissance Technologies LLC | 116.0K | $158.9K |
| 4 | Geode Capital Management, LLC | 111.6K | $153.0K |
| 5 | Westside Investment Management, Inc. | 50.0K | $68.6K |
| 6 | Voss Capital, LP | 50.0K | $68.5K |
| 7 | Blackrock, Inc. | 45.3K | $62.0K |
| 8 | Dimensional Fund Advisors LP | 38.1K | $52.1K |
| 9 | Horizon Kinetics Asset Management LLC | 26.4K | $36.1K |
| 10 | Davenport & Co LLC | 23.8K | $32.6K |